Zealand CEO: We are obligated to be ambitious
![](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article7575831.ece/ALTERNATES/schema-16_9/Britt%2520Meelby%2520Jensen2.jpg)
It takes more than a quarter characterized by limited revenue from licensing deals and massive development costs to make Zealand Pharma CEO Britt Meelby Jensen waver.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Analyst: Novo’s product is superior, but…
For abonnenter
Zealand chief is pleased with quiet quarter
For abonnenter
Zealand CEO: A news-heavy year
For abonnenter